Alzheimer Disease: From Molecular Biology to Theraphy

Front Matter....Pages i-xiv
Front Matter....Pages 1-1
Apoptosis and Alzheimer’s Disease: A Self-Assembly and the Initiation of Apoptosis by Plasma Membrane Receptor Cross-Linking....Pages 99-106
NMDA Receptor Dysfunction in Alzheimer’s Disease....Pages 107-112
Role of Neuron-Glia Interactions in Brain Energy Metabolism: Implications for Neurodegenerative Disorders....Pages 113-118
Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer’s Disease....Pages 119-124
Cortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy....Pages 125-131
Criteria for the Clinical Diagnosis of Alzheimer’s Disease: Transcultural Aspects....Pages 3-6
Clinical and Neuropathological Findings from CERAD....Pages 7-11
Differentiating Alzheimer Disease and Vascular Dementia: Reframing the Question....Pages 13-17
Basis of Structural Alzheimer Disease and Some Pathogenic Concepts....Pages 19-23
Regional Distribution of Neuropathological Changes in Alzheimer’s Disease....Pages 25-29
Alzheimer Neurofibrillary Degeneration: A Feasible and Key Target for Therapeutics....Pages 31-36
Diabetes and Dementia: A Retrospective Neuropathologic Study of Old Diabetics Compared to Non-Diabetic Controls....Pages 37-46
Isoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer ’s Disease....Pages 47-53
Apolipoprotein E4 and Cholinergic Activity in Alzheimer’s Disease....Pages 55-60
A New Focus on Cytoskeletal Therapy in Alzheimer’s Disease....Pages 61-65
Novel Cathepsin D Inhibitors Prevent the β-Secretase-Derived Intracellular Formation of a 12 kDa Potentially Amyloidogenic Product in Human Cells....Pages 67-73
Cellular and Test Tube Models of Amyloid-βFormation....Pages 75-80
Effects of β-Amyloid (1–40) Peptide Injection in the Nucleus Basalis....Pages 81-85
ß-Amyloid Precursor Protein — Role in Cognitive Brain Function?....Pages 87-90
Peptides Inhibitor of Amyloidogenesis in Alzheimer’s Disease....Pages 91-97
Front Matter....Pages 1-1
APP Knockout and APP Over-Expression in Transgenic Mice....Pages 133-136
Alpha2c-Adrenoceptor Overexpressing Mice as a Model to Study Cognitive Functions of Alpha2-Adrenoceptors....Pages 137-143
β-App-751 Transgenic Mice: Deficits in Learning and Memory....Pages 145-150
Front Matter....Pages 151-151
Central and Peripheral Consequences of Cholinergic Imbalance in Alzheimer’s Disease....Pages 153-157
The Anatomy of Monoaminergic-Cholinergic Interactions in the Primate Basal Forebrain....Pages 159-164
Pharmacological Induction of Cholinergic Hypofunction as a Tool for Evaluating Cholinergic Therapies....Pages 165-170
Rational Design of New Acetylcholinesterase Inhibitors....Pages 171-177
Advances in Understanding Cholinergic Brain Neurons: Implications in the use of Citicoline (CDP-Choline) to Treat Stroke....Pages 179-185
Cholinesterase Inhibitors Do More than Inhibit Cholinesterase....Pages 187-204
Long-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality....Pages 205-209
Cholinesterase Inhibitors: An Overview of their Mechanisms of Action....Pages 211-215
Preclinical Pharmacology of Metrifonate: A Promise for Alzheimer Therapy....Pages 217-221
Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease....Pages 223-230
Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and β-APP Processing....Pages 231-237
An Overview of the Development of SDZ ENA 713, A Brain Selective Cholinesterase Inhibitor....Pages 239-243
Preclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor....Pages 245-250
P11467: An Orally-Active Acetylcholinesterase Inhibitor and α 2 -Adrenoceptor Antagonist for Alzheimer’s Disease....Pages 251-255
Cholinesterase Inhibitors as Therapy in Alzheimer’s Disease: Benefit to Risk Considerations in Clinical Application....Pages 257-266
Front Matter....Pages 267-267
Molecular Histochemistry of Nicotinic Receptors in Human Brain....Pages 269-273
The Nicotinic Cholinergic System and ß-Amyloidosis....Pages 275-279
Front Matter....Pages 267-267
RJR-2403: A CNS-Selective Nicotinic Agonist with Therapeutic Potential....Pages 281-286
ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action....Pages 287-291
Biochemistry, Pharmacodynamics and Pharmacokinetics of CI-1002, A Combined Anticholinesterase and Muscarinic Antagonist....Pages 293-297
Muscarinic Partial Agonists in the Symptomatic Treatment of Alzheimer’s Disease....Pages 299-303
Safety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer’s Disease....Pages 305-310
Pharmacological Characterization of PD151832, an M1 Muscarinic Receptor Agonist....Pages 311-315
Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer’s Disease....Pages 317-322
Free Radical Scavengers Block the Actions of β-Amyloid on Neurons in Tissue Culture....Pages 323-327
Therapeutic Strategies in Alzheimer’s Disease....Pages 329-336
New Synthetic Bioantioxidants — Acetylcholinesterase (AChE) Inhibitors....Pages 337-342
Rationale to Treat Alzheimer’s Disease with Selegiline — Can We Prevent the Progression of the Disease?....Pages 343-347
Inflammatory Processes — Anti-Inflammatory Therapy....Pages 349-353
Propentofylline — Preclinical Data....Pages 355-359
Propentofylline (HWA 285): a Subgroup Analysis of Phase III Clinical Studies in Alzheimer’s Disease and Vascular Dementia....Pages 361-365
Anapsos: New Therapeutic Strategies for Neurodegeneration and Brain Aging with Neuroimmunotrophic Factors....Pages 367-372
Front Matter....Pages 373-373
Clinical Trials to Prevent Alzheimer’s Disease in a Population At-Risk....Pages 375-379
Effects on Decline or Deterioration....Pages 381-385
The Bridging Study: Optimizing the Dose for Phase II/III....Pages 387-391
Assessment of Therapeutic Strategies for Slowing Progression of Alzheimer’s Disease....Pages 393-397
Potential for Progress in the Therapeutics of Alzheimer’s Disease; Unanswered Questions....Pages 399-406
Front Matter....Pages 373-373
The Alzheimer’s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials....Pages 407-411
An Item Pool to Assess Activities of Daily Living in Alzheimer’s Disease....Pages 413-417
Severe Impairment Battery: A Potential Measure for AD Clinical Trials....Pages 419-423
Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)....Pages 425-429
Advantages of the “Time-Index” Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit....Pages 431-434
Pet-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain....Pages 435-438
Pet Imaging of Nicotinic Receptors in Alzheimer’s Disease — Implication with Diagnosis and Drug Treatment....Pages 439-444
Cerebral Spect Imaging: Advances in Radio Pharmaceuticals and Quantitative Analysis....Pages 445-450
 In Vivo Imaging of Anticholinesterase Drugs Used in Alzheimer’s Disease....Pages 451-456
Spect Scan and Efficacy of Therapy in Alzheimer’s Disease....Pages 457-461
MRI and Cognitive Markers of Progression and Risk of Alzheimer Disease....Pages 463-468
Brain Mapping and Transcranial Doppler Ultrasonography in Alzheimer Disease Drug Monitoring....Pages 469-473
Apoe Genotype and MRI volumetry: Implication for Therapy....Pages 475-480
Group Psychotherapy....Pages 481-486
Non Cognitive Symptoms in Alzheimer’s Disease....Pages 487-493
Depression and Alzheimer’s Disease....Pages 495-499
Psychomotor Therapy and Alzheimer’s Disease....Pages 501-505
Behavioral Techniques for Treatment of Patients with Alzheimer’s Disease....Pages 507-511
Treatment of Psychosocial Disturbances....Pages 513-520
Serotoninergic Symptomatology in Dementia....Pages 521-526
Front Matter....Pages 527-527
Informed Consent and Alzheimer Disease Research: Institutional Review Board Policies and Practices....Pages 529-534
Legal Issues in Alzheimer Disease Research in France....Pages 535-540
Ethical Problems in Therapeutic Research in Alzheimer’s Disease Patients....Pages 541-547
Making Consent Work in Alzheimer Disease Research....Pages 549-554
Industry Perspectives on the Marketing of Anti-Alzheimer Disease Therapy....Pages 555-560
Codem: A Longitudinal Study on Alzheimer Disease Costs....Pages 561-565
Health Economic Aspects of Alzheimer’s Disease and the Implications for Drug Development and Pricing....Pages 567-572
International Working Group for the Harmonization of Dementia Drug Guidelines: A Progress Report....Pages 573-577
Developing Safe and Effective Antidementia Drugs....Pages 579-584
A Japanese Perspective on the Work of the International Group on Harmonization of Drug Guidelines....Pages 585-589
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association....Pages 591-597
Back Matter....Pages 599-613